ArticleVaccine2009
Intradermal immunization improves protective efficacy of a novel TB vaccine candidate.
Article in Vaccine, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06627257 (A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Participants in Areas Endemic for Leprosy), which is not on this map. Cited by 52 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Phase 1b, Double-Blind, Randomized, Placebo-Controlled, Antigen Dose-Escalation Clinical Trial to Evaluate the Safety, Tolerability, and Immunogenicity of LEP-F1 + GLA-SE in Healthy Adult Participants in Areas Endemic for Leprosy
Who cites it
52 citing papers in PubMed, 91 citations in OpenAlex.
- Multifaceted DosR proteins of Mycobacterium tuberculosis: emerging roles for tuberculosis control.Archives of microbiology · 2026Review
- The Impact of Animal Models and Strain Standardization on the Evaluation of Tuberculosis Vaccine Efficacy.Vaccines · 2025Review
- Evaluation of Immunogenicity ofVaccines · 2025Article
- Type VII secretion system gene mutations driving global mycobacterium tuberculosis transmission revealed by whole genomic sequence.Frontiers in cellular and infection microbiology · 2025Article
- Preventive effects ofFrontiers in immunology · 2023Article
- Targeting TLR4 during vaccination boosts MAdCAM-1Science immunology · 2022Article
- B21 DNA vaccine expressing ag85b, rv2029c, and rv1738 confers a robust therapeutic effect against latentFrontiers in immunology · 2022Article
- Article
- Article
- Vitamin D modulates human macrophage response to Mycobacterium tuberculosis DNA.Tuberculosis (Edinburgh, Scotland) · 2019Article
- Article
- Rational combinations of in vivo cancer antigen priming and adoptive T-cell therapy mobilize immune and clinical responses in terminal cancers.Cancer immunology, immunotherapy : CII · 2018Article
- Frequent transmission of the Mycobacterium tuberculosis Beijing lineage and positive selection for the EsxW Beijing variant in Vietnam.Nature genetics · 2018Article
- LepVax, a defined subunit vaccine that provides effective pre-exposure and post-exposure prophylaxis ofNPJ vaccines · 2018Article
- Article
- The TLR4 Agonist Vaccine Adjuvant, GLA-SE, Requires Canonical and Atypical Mechanisms of Action for TH1 Induction.PloS one · 2016Article
- The microbiome at the pulmonary alveolar niche and its role in Mycobacterium tuberculosis infection.Tuberculosis (Edinburgh, Scotland) · 2015Review
- Whole Tumor Antigen Vaccines: Where Are We?Vaccines · 2015Review
- From mouse to man: safety, immunogenicity and efficacy of a candidate leishmaniasis vaccine LEISH-F3+GLA-SE.Clinical & translational immunology · 2015Article
- Motivations and concerns about adolescent tuberculosis vaccine trial participation in rural Uganda: a qualitative study.The Pan African medical journal · 2015Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
Abstract
We have developed the Mycobacterium tuberculosis (Mtb) fusion protein (ID83), which contains the three Mtb proteins Rv1813, Rv3620 and Rv2608. We evaluated the immunogenicity and protective efficacy of ID83 in combination with several emulsion-formulated toll-like receptor agonists. The ID83 subunit vaccines containing synthetic TLR4 or TLR9 agonists generated a T helper-1 immune response and protected mice against challenge with Mtb regardless of route. The ID83 vaccine formulated with gardiquimod (a TLR7 agonist) also resulted in a protective response when administered intradermally, whereas the same vaccine given subcutaneously failed to provide protection. This highlights the need to explore different routes of immunization based on the adjuvant formulations used.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.